title: Hemolytic disease of the fetus and newborn due to multiple maternal antibodies.
abstract: OBJECTIVE
  The objective of the study was to determine whether women with combinations of red blood cell antibodies are more likely to develop significant hemolytic disease of the fetus and newborn than those with single antibodies.
  
  
  METHODS
  A retrospective exposure cohort study was conducted of pregnant women with red blood cell antibodies. The development of significant hemolytic disease of the fetus and newborn was then compared between patients with single antibodies and those with multiple antibodies. Data analysis was limited to pregnancies delivering since the year 2000.
  
  
  RESULTS
  Thirteen percent of the patients referred to our program had multiple red blood cell antibodies. Odds of developing significant hemolytic disease of the fetus and newborn for patients with anti-Rh(D) combined with at least 1 additional red blood cell antibody were 3.65 times the odds for women with anti-Rh(D) antibodies in isolation (95% confidence interval, 1.84-7.33). In the setting of multiple antibodies including anti-Rh(D), Rh-positive fetuses/neonates have an increased odds of developing significant hemolytic disease even if the fetus is negative for the other corresponding red blood cell antigen.
  
  
  CONCLUSIONS
  Women with multiple red blood cell antibodies are more likely to develop significant hemolytic disease of the fetus and newborn than those with a single antibody especially in the presence of anti-(Rh)D. This pathophysiology may suggest a more aggressive immune response in women who develop more than 1 red blood cell antibody.
authors: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Wexner Medical Center, The Ohio State University, Columbus, OH. Electronic address: kara.markham@osumc.edu.
authors: Kara Beth
authors: KB
authors: Markham
authors: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Wexner Medical Center, The Ohio State University, Columbus, OH.
authors: Karen Q
authors: KQ
authors: Rossi
authors: College of Public Health, The Ohio State University, Columbus, OH.
authors: Haikady N
authors: HN
authors: Nagaraja
authors: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Wexner Medical Center, The Ohio State University, Columbus, OH.
authors: Richard W
authors: RW
authors: O'Shaughnessy
mesh_terms: D000328:Adult; D004899:Erythroblastosis, Fetal / Q000097:blood* / Q000453:epidemiology / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007518:Isoantibodies / Q000276:immunology; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System / Q000276:immunology*; D018029:Rho(D) Immune Globulin; D018570:Risk Assessment; D055815:Young Adult
chemical_list: D007518:Isoantibodies; C061961:RHO(D) antibody; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin
keywords: alloimmunization; hemolytic disease of the fetus and newborn; red blood cell antibodies